Clinical Trials Directory

Trials / Completed

CompletedNCT05227586

Adjunctive Right Atrial Ablation for Persistent Atrial Fibrillation With Right Atrial Enlargement

Status
Completed
Phase
Study type
Observational
Enrollment
195 (actual)
Sponsor
Shanghai Chest Hospital · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers

Summary

This is retrospective cohort study testing whether patients with persistent atrial fibrillation and right atrial enlargement may benefit from adjunctive right atrial ablation.

Detailed description

This is retrospective cohort study testing whether patients with persistent atrial fibrillation and right atrial enlargement may benefit from adjunctive RA ablation. We enrolled 65 patients with persistent atrial fibrillation and right atrial enlargement received adjunctive right atrial ablation. These patients were 1:2 match with 130 patients received left atrial ablation only. Atrial fibrillation recurrence rate and other paremeters were analyzed to evaluate the efficacy of adjunctive right atrial ablation in this subset of patients.

Conditions

Interventions

TypeNameDescription
PROCEDURECircumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablationPatients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping and left atrial driver ablation.
PROCEDURECircumferential pulmonary vein isolation + linear ablation + bi-atrial mapping + left atrial driver ablation + right atrial driver ablationPatients receive circumferential pulmonary vein isolation and linear ablation (ablation of a roof line and a mitral isthmus line) combined with bi-atrial mapping , left atrial driver ablation and right atrial driver ablation.

Timeline

Start date
2021-11-01
Primary completion
2022-01-01
Completion
2022-01-20
First posted
2022-02-07
Last updated
2022-02-07

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05227586. Inclusion in this directory is not an endorsement.